Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients

HIV Medicine
X DuvalJ-L Vildé

Abstract

There is evidence to suggest a pharmacokinetic-pharmacodynamic relationship in HIV-infected patients receiving protease inhibitor (PI)-containing highly active antiretroviral therapy (HAART); however, the effective trough PI plasma concentrations achieved have not been precisely determined. The relationship between HIV viral load and concomitant PI trough plasma concentration (C(trough)) was evaluated in 101 patients receiving at least 4 months of thrice daily indinavir (IDV)-containing (n=68) or nelfinavir (NFV)-containing (n=33) HAART. The more discriminating C(trough) efficacy thresholds were determined statistically for each PI by using the raw C(trough) and the time-corrected C(trough), using the precise delay since the last PI intake and the half-life of each PI. For IDV (P=0.002) and NFV (P=0.019) median C(trough) levels were higher in patients with undetectable viral load [0.23 mg/L (n=30) and 2.3 mg/L (n=16) respectively] than in patients with detectable viral load [0.11 mg/L (n=38) and 0.6 mg/L (n=17) respectively]. C(trough) levels of IDV (r=-0.45; P<0.0001) and NFV (r=-0.43; P=0.011) were correlated with the concomitant viral load. The more discriminating C(trough) efficacy thresholds were estimated statistically as...Continue Reading

References

Sep 30, 1995·Lancet·I Loussert-AjakaS Saragosti
Oct 1, 1998·Antiviral Research·C Scholtissek, R G Webster
Jul 3, 1999·Pharmacotherapy·E P AcostaC V Fletcher
Jan 14, 2000·JAMA : the Journal of the American Medical Association·D V HavlirD D Richman
Jun 22, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E P AcostaC V Fletcher
Nov 23, 2000·AIDS·P L AndersonC V Fletcher
Dec 20, 2000·Antimicrobial Agents and Chemotherapy·T N KakudaC V Fletcher
Apr 25, 2001·British Journal of Clinical Pharmacology·D J BackC Merry
Jun 28, 2002·The Annals of Pharmacotherapy·Craig R RaynerGregory J Duncan
Aug 22, 2002·Clinical Pharmacology and Therapeutics·Michael KurowskiAlexander Mrozikiewicz

❮ Previous
Next ❯

Citations

Jan 24, 2012·International Journal of Nanomedicine·Shantanu BalkundiHoward E Gendelman
Jul 27, 2006·Expert Opinion on Drug Metabolism & Toxicology·Montserrat Olmo, Daniel Podzamczer
May 25, 2005·Fundamental & Clinical Pharmacology·Karl BrendelUNKNOWN Cophar 1-ANRS 102 Trial Group
Aug 9, 2011·Thérapie·Aurélie Barrail-TranUNKNOWN Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique
Sep 15, 2016·Expert Review of Clinical Pharmacology·Baralee PunyawudhoKiat Ruxrungtham
Apr 10, 2007·Therapeutic Drug Monitoring·Fidéline CollinUNKNOWN ANRS CO8 Aproco-Copilote Study Group
Nov 27, 2008·American Journal of Physiology. Endocrinology and Metabolism·Julia KovsanAssaf Rudich
Oct 18, 2005·Drugs·Caroline M PerryRisto S Cvetković

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.